Exact Sciences Corporation (EXAS) Balance Sheet

The consistent debt level of $2.5 billion over the last four quarters indicates a reliance on fixed-income markets to fund operations rather than internal cash generation. Investors should monitor whether this leverage remains sustainable if the company fails to achieve consistent GAAP profitability in the near term.

While the liquidity position has improved significantly throughout 2025, the volatility in cash balances suggests that working capital management remains a critical factor in maintaining operational stability. The current ratio provides a reasonable cushion, yet the underlying reliance on debt financing warrants caution regarding future liquidity requirements.

The high concentration of goodwill relative to total assets suggests that the company's book value is sensitive to potential impairment charges if the acquired oncology assets fail to meet long-term growth expectations. This asset mix highlights the company's strategy of inorganic growth, which carries inherent risks regarding the valuation of intangible assets.

The persistent negative retained earnings highlight the company's historical focus on market share acquisition over immediate profitability. This trend suggests that equity value is currently driven more by growth expectations than by the accumulation of earned capital, which may limit the company's flexibility in future capital allocation.